Mersana Therapeutics (MRSN)
(Real Time Quote from BATS)
$3.27 USD
-0.07 (-2.10%)
Updated Apr 19, 2024 03:34 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Mersana Therapeutics, Inc. (MRSN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.38 | $9.00 | $5.00 | 91.02% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Mersana Therapeutics, Inc. comes to $6.38. The forecasts range from a low of $5.00 to a high of $9.00. The average price target represents an increase of 91.02% from the last closing price of $3.34.
Analyst Price Targets (8 )
Broker Rating
Mersana Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.44 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy, representing 77.78% of all recommendations. A month ago, Strong Buy represented 77.78%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 1 | 1 |
ABR | 1.44 | 1.44 | 1.44 | 2.56 | 2.56 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/29/2024 | Wedbush Securities | David M Nierengarten | Hold | Strong Buy |
2/29/2024 | Robert W. Baird & Co. | Colleen M Kusy | Hold | Hold |
2/29/2024 | Truist Securities | Asthika S Goonewardene | Hold | Strong Buy |
2/29/2024 | Guggenheim Securities | Michael Schmidt | Hold | Strong Buy |
2/29/2024 | BTIG | Kaveri Pohlman | Hold | Strong Buy |
11/7/2023 | SVB Securities | Jonathan W Chang | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.44 |
ABR (Last week) | 1.44 |
# of Recs in ABR | 9 |
Average Target Price | $6.38 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -0.18 |